

IMPAX LABORATORIES INC

FORM 8-K (Current report filing)

Filed 03/14/05 for the Period Ending 03/14/05

Address	30831 HUNTWOOD AVENUE HAYWARD, CA 94544
Telephone	510-240-6000
CIK	0001003642
Symbol	IPXL
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	12/31

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

FORM 8-K

**CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): March 14, 2005

Impax Laboratories, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

0-27354

65-0403311

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

30831 Huntwood Ave., Hayward, CA

94544

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code (510) 476-2000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01 REGULATION FD DISCLOSURE

On March 14, 2005, Impax Laboratories, Inc. (the "Company") issued a press release announcing that it intends to file a Notification of Late Filing on Form 12b-25 with the SEC for its Form 10-K for the year 2004. A copy of the press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits.

99.1 - Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMPAX LABORATORIES, INC.

Date: March 14, 2005

By /s/ Cornel C. Spiegler

Name: Cornel C. Spiegler

Title: Chief Financial Officer

COMPANY CONTACTS: INVESTOR RELATIONS CONTACTS:

IMPAX Laboratories, Inc.

Barry R. Edwards, CEO
(215) 933-0323 Ext. 4360
Larry Hsu, Ph.D. President
(510) 476-2000 Ext. 1111
Cornel C. Spiegler, CFO
(215) 289-2220 Ext. 1706
www.impaxlabs.com

Lippert/Heilshorn & Associates, Inc.

Kim Sutton Golodetz (kgolodetz@lhai.com)
(212) 838-3777
Bruce Voss (bvoss@lhai.com)
(310) 691-7100
www.lhai.com

MARCH 10, 2005

IMPAX TO FILE 2004 10-K FILING EXTENSION

HAYWARD, Calif.--(BUSINESS WIRE)--March 14, 2005--IMPAX Laboratories, Inc. (Nasdaq:IPXL - News) today announced that it intends to file a Notification of Late Filing on Form 12b-25 with the Securities and Exchange Commission (SEC) for its Form 10-K for the year 2004. The Company expects to be able to file the 10-K by the end of March, within the 15 day extension provided by the SEC. IMPAX will issue a press release to announce when it plans to release fourth quarter and year-end 2004 results and details regarding its related quarterly conference call.

The Company is filing for the extension to allow time to complete the year-end financial closing and audit, including reviewing necessary information from its strategic partner Teva for certain commercial products sold under its agreement with them. The restatements announced last quarter significantly increased the complexity and scope of the year-end audit process. The extension also is needed to allow additional time to complete the extensive Sarbanes-Oxley Section 404 internal controls requirements, necessary for the first time with this year's filing, and additional time for the Company to investigate and evaluate potential material weaknesses or potential significant deficiencies in connection with the internal control 404 evaluation.

IMPAX Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. IMPAX markets its generic products through its Global Pharmaceuticals division and intends to market its branded products through the IMPAX Pharmaceuticals division. Additionally, where strategically appropriate, IMPAX has developed marketing partnerships to fully leverage its technology platform. IMPAX Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more information, please visit the Company's Web site at: www.impaxlabs.com.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

To the extent any statements made in this news release contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Impax's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, Impax's ability to obtain sufficient capital to fund its operations, the difficulty of predicting FDA filings and approvals, consumer acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, Impax's ability to successfully develop and commercialize pharmaceutical products, Impax's reliance on key strategic alliances, the uncertainty of patent litigation, the availability of raw materials, the regulatory environment, dependence on patent and other protection for innovative products, exposure to product liability claims, fluctuations in operating results and other risks detailed from time to time in Impax's filings with the Securities and Exchange Commission. Forward-looking statements speak only as to the date on which they are made, and Impax undertakes no obligation to update publicly or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.

###